Mynosys Cellular Devices, Inc. has received 510(k) clearance from the U.S. FDA for its Zepto™ Capsulotomy System for performing lens capsulotomy during cataract surgery.
Zepto reportedly uses a proprietary combination of calibrated suction and a 4-millisecond multipulse energy algorithm to produce high quality capsulotomies. The device can reportedly be used through a 2.2 mm incision and integrates seamlessly into the standard cataract surgery routine to enhance surgical efficiency and patient flow. Zepto can reportedly be used in not only simple cataract surgery cases, but also challenging ones with small pupils, zonulopathies, corneal opacities, and in intumescent cataracts. And Zepto can provide personalized capsulotomies tailored to the specific visual axis of individual patients.
According to Mynosys, Zepto already has CE Mark and was launched commercially earlier this year in India and Germany.
Click here to read the full press release.
Like what you read? Follow OphthalmologyWeb to keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.
Source: Mynosys Cellular Devices, Inc.